Hornby Zachary 4

Accession 0000950170-24-099306

CIK 0001782303other

Filed

Aug 19, 8:00 PM ET

Accepted

Aug 20, 7:10 PM ET

Size

20.9 KB

Accession

0000950170-24-099306

Form 4

Period: 2024-08-19

DirectorPresident & CEO

Transactions

Disposition to Issuer
Stock Option
2024-08-19−471,282→ 0 total
Exercise: $4.10Exp: 2033-06-12→ Common Stock (471,282 underlying)
Award
Stock Option
2024-08-19+471,282→ 471,282 total
Exercise: $3.56Exp: 2033-06-12→ Common Stock (471,282 underlying)
Award
Stock Option
2024-08-19+162,343→ 162,343 total
Exercise: $3.56Exp: 2034-03-26→ Common Stock (162,343 underlying)
Disposition to Issuer
Stock Option
2024-08-19−256,410→ 0 total
Exercise: $4.10Exp: 2031-06-06→ Common Stock (256,410 underlying)
Disposition to Issuer
Stock Option
2024-08-19−257,207→ 0 total
Exercise: $8.19Exp: 2034-02-14→ Common Stock (257,207 underlying)
Disposition to Issuer
Stock Option
2024-08-19−162,343→ 0 total
Exercise: $16.00Exp: 2034-03-26→ Common Stock (162,343 underlying)
Award
Stock Option
2024-08-19+256,410→ 256,410 total
Exercise: $3.56Exp: 2031-06-06→ Common Stock (256,410 underlying)
Award
Stock Option
2024-08-19+257,207→ 257,207 total
Exercise: $3.56Exp: 2034-02-14→ Common Stock (257,207 underlying)

Footnotes (6)

[F1]The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021.
[F2]On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 6, all other terms of the option remain unchanged.
[F3]The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023.
[F4]The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
[F5]The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024.
[F6]The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.

Documents

1 file

Boundless Bio, Inc.

CIK 0001782303

Entity typeother